Genmab A (GMAB) Retained Earnings (2019 - 2026)
Genmab A's (GMAB) quarterly Retained Earnings came in at -$340.0 million in Q1 2026, down 59.62% YoY from -$842.1 million in Q1 2025, and down 87.85% on a QoQ basis from -$181.0 million in Q4 2025.
Genmab A (GMAB) Retained Earnings (2019 - 2026) Analysis & Trends
Genmab A (GMAB) has 6 years of Retained Earnings data on file, last reported at -$340.0 million in Q1 2026.
- Quarterly Retained Earnings fell 59.62% year-over-year to -$340.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$340.0 million (down 59.62% YoY) and the FY2025 annual result came in at -$181.0 million, down 105.34% from the prior year.
- Retained Earnings fell to -$340.0 million in Q1 2026, from -$181.0 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $3.4 billion in Q4 2024 to a low of -$340.0 million in Q1 2026.
- A 4-year average of $711.6 million and a median of -$204.0 million in 2025 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings advanced 23.93% — and 2025, when it slumped 105.34%.
- Tracing GMAB's Retained Earnings over 4 years: stood at $2.7 billion in 2023, then climbed by 23.93% to $3.4 billion in 2024, then tumbled by 105.34% to -$181.0 million in 2025, then slumped by 87.85% to -$340.0 million in 2026.
- The last three Retained Earnings figures came in at -$340.0 million (Q1 2026), -$181.0 million (Q4 2025), and -$204.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | 4.42 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.42 Bn |
| Mar 31, 2026 | -340.00 Mn |
| Dec 31, 2025 | -181.00 Mn |
| Sep 30, 2025 | -204.00 Mn |
| Jun 30, 2025 | -210.00 Mn |
| Mar 31, 2025 | -213.00 Mn |
| Dec 31, 2024 | 3.39 Bn |
| Dec 31, 2023 | 2.74 Bn |
| Sep 30, 2020 | 74.00 |
| Dec 31, 2019 | 98.00 |
| Sep 30, 2019 | 100.39 Mn |